In 2022, the mortality rate due to Alzheimer's disease was 36 deaths per 100,000 people. This statistic displays the annual Alzheimer's disease mortality rate in the United States from 2000 to 2022. Scientists believe that early detection of Alzheimer's can be the best way to prevent or slow the course of the disease. Alzheimer’s disease Alzheimer’s disease, a progressive and incurable brain disease, is among the top ten leading causes of death in the U.S. as well as worldwide. Furthermore, over the past two decades, the number of deaths due to Alzheimer’s and other dementias in the United States increased by over 140 percent. As with other dementias, Alzheimer’s commonly affects older individuals, although it can be diagnosed earlier on in life. In the United States, the majority of people with Alzheimer’s disease are over 75 years of age. Initial symptoms include difficulties in memory and mood changes, but the disease gradually progresses to impair communication and judgment, behavioral changes, and deficits in movement and motor skills, such as difficulties with swallowing, which often becomes a contributing cause of death. Care and treatment The cost of care for individuals with Alzheimer’s is expected to increase over the next couple of decades, with costs to Medicare and Medicaid expected to reach 637 billion U.S. dollars by 2050. Due to the increasing burden of Alzheimer’s and other dementias on healthcare and social systems, research into treatment and prevention is a major focus. Several major pharmaceutical companies currently have multiple drugs for Alzheimer’s treatment in various stages of development; other research is focused on identifying early brain changes associated with the disease in order to provide early diagnosis and intervention. Furthermore, personal health strategies include reducing modifiable risk factors commonly associated with cardiovascular health, such as quitting smoking, maintaining a healthy diet, and staying socially, mentally, and physically active.

In 2021, the U.S. states with the highest death rates from Alzheimer’s disease were Mississippi, Alabama, and Vermont. At that time, the death rate due to Alzheimer’s disease in South Dakota was 44 per 100,000 population. However, the state with the highest total number of deaths due to Alzheimer’s disease that year was California, with 16,911 such deaths.

Alzheimer’s disease among the leading causes of death in the U.S. As of 2021, Alzheimer’s disease was the seventh leading cause of death in the United States. The death rate due to Alzheimer’s disease in the U.S. has more than doubled over the past couple of decades, reaching an estimated 37 deaths per 100,000 population in 2019. Age is the biggest risk factor for Alzheimer’s, so it is no surprise that the death rate from the disease increases significantly with age. For example, in 2021, the Alzheimer’s death rate among those aged 85 years and older was 1,244 per 100,000 population, compared to a rate of 214 per 100,000 population among those aged 75 to 84 years.

How many people in the U.S. have Alzheimer’s disease? It was estimated that in 2020, around 6.1 million people aged 65 years and older in the United States were living with Alzheimer’s disease. This figure is expected to increase to around 8.5 million by the year 2030. A rise in life expectancy and the increasing elderly population go some ways in explaining the increase in Alzheimer's in the United States. However, a growing number of Americans are also living with known modifiable Alzheimer’s risk factors such as high blood pressure, obesity, and diabetes.

The age-specific mortality rate of alzheimer's disease at all ages in Canada decreased by 0.8 deaths (-5.76 percent) compared to the previous year. In 2023, the age-specific mortality rate thereby reached its lowest value in recent years.

In 2022, there were ***** deaths caused by Alzheimer's disease per 100,000 population in South Korea. One of several neurodegenerative diseases, it often leads to dementia and is more commonly found in the elderly.

In 2022, there were around *** deaths per 100,000 adults aged 65 to 69 years in Canada due to Alzheimer's disease. This statistic shows the death rate for Alzheimer's disease among adults in Canada in 2022, by age at time of death.

BackgroundWith global aging, Alzheimer’s disease (AD) and other dementias have emerged as significant health threats to the older adults, garnering considerable attention due to their impact on public health. Despite the substantial burden of dementia in Asia, targeted research remains limited. This study aims to assess the current burden, future trends, risk factors, and inequalities in Asia.MethodThe GBD 2021 study was utilized to evaluate the numbers and age-standardized rates (ASRs) of prevalence, mortality, and disability-adjusted life-years (DALYs) of AD and other dementias from 1990 to 2021. Joinpoint regression analysis was performed to assess the trends during this period, while the Autoregressive Integrated Moving Average (ARIMA) model was employed to predict future trends. Additionally, the relationship between disease burden and sociodemographic index (SDI) was also analyzed.ResultsIn 2021, Asia experienced a 250.44% increase in prevalent cases, a 297.34% rise in mortality, and a 249.54% surge in DALYs for AD and other dementias compared to 1990. Meanwhile, the age-standardized prevalence rate, age-standardized mortality rate, and age-standardized DALY rate also exhibited varying degrees of rise from 1990 to 2021. Demographically, the disease burden was higher in women and those aged 65 and above. Regionally, the burden was highest in East Asia and relatively low in South and Central Asia. Nationally, China, India, Japan, and Indonesia reported the most cases. Over the next 15 years, the age-standardized prevalence rate in Asia is expected to peak in 2028 before declining, while the age-standardized mortality rate is anticipated to keep rising. An overall “V” shaped association was found between sociodemographic index (SDI) and the age-standardized DALY rate in Asia. Only smoking, high fasting plasma glucose (FPG), and high BMI were identified as causal risk factors within the GBD framework.ConclusionThe burden of AD and other dementias in Asia has significantly increased over the past three decades and is expected to persistently impact Asian populations, particularly in developing countries experiencing rapid demographic shifts. Women and the older adult should be a focus of attention. It is imperative to implement targeted prevention and intervention strategies, enhance chronic disease management, and control risk factors.

BackgroundDementia, one of the top 10 causes of death globally, imposes significant health and socioeconomic/socioeconomic burdens, with prevalence projected to reach 82 million by 2030. High fasting plasma glucose (HFPG) is a prominent modifiable risk factor for dementia in 2021. This study aims first to examine the global trend in dementia burden and the disability-adjusted life years and death attributable to HFPG from 1990 to 2021 and second to define age-specific disparities in dementia burden among older populations.MethodsUsing data from the Global Burden of Diseases Study (GBD) 2021, this research evaluated the incidence, prevalence, deaths, disability-adjusted life years (DALYs), and HFPG-attributable burden related to Alzheimer’s disease and other dementias (ADOD). The estimated annual percentage change was calculated to qualify the burden change of ADOD.ResultsThere was a significant rise in the ADOD burden globally, with over 56.9 million prevalent cases and 2.0 million deaths in 2021. the incidence and prevalence were positively correlated with HFPG-related summary exposure value. The HFPG-attributable ADOD burden has increased worldwide over time. Globally, the 60 to 74 age groups suffered a prominent rise in the burden and HFPG-attributable burden of ADOD.ConclusionThe global burden and HFPG-attributable ADOD burden have remained prominent and have increased increase over the past 32 years. The ASIR and ASPR showed positive correlations with the SEV related to HFPG. Notably, the 60 to 74 age groups suffered a prominent rise in burden and HFPG attributable to the DALYs rate of ADOD over time. Moreover, a prominent positive correlation was observed between the incidence and prevalence rate with the SEVs related to HFPG occurred in the population aged 60 to 74 years old. Therefore, HFPG should be emphasized in strategic priorities for controlling the ADOD burden.

Deaths registered in 2019 in England and Wales due to dementia and Alzheimer's disease, by sex, age group, ethnicity, region and place of occurrence. Includes analysis of comorbidities.

In 2019, the death rate for Alzheimer's disease among men in the United States aged 65 years and older was around 187 per 100,000 population, compared to a rate of 263 per 100,000 population among women. This statistic shows the death rates for Alzheimer's disease among adults in the United States aged 65 years and older from 2000 to 2019, by gender.

BackgroundAlzheimer’s disease and other dementias (ADOD) pose a significant and escalating global public health challenge, particularly among the aging populations. Emerging evidence has identified high fasting plasma glucose (HFPG) as a major modifiable risk factor for ADOD, linking impaired glucose metabolism to cognitive decline and neurodegeneration. Despite this association, the comprehensive impact of HFPG on the global burden of ADOD has not been fully elucidated. Understanding the extent to which HFPG contributes to ADOD is crucial for developing targeted interventions and optimizing healthcare resource allocation to address this growing concern.MethodsUsing Global Burden of Disease data (GBD 2021), we analyzed the global HFPG-related ADOD burden from 1990 to 2021 using an age-period-cohort framework and predicted trends for 2050. A Shiny platform was developed to visualize the disease burden and trends across 204 countries and regions.ResultsIn 2021, approximately 15% of ADOD deaths and disability-adjusted life years (DALYs) were attributed to HFPG, a 271.05% increase from 1990. The incidence rate rose from 47.07 to 66.42, indicating poor control. The mortality rate from HFPG-ADOD increased by 305.81%. The primary burden was among the 80–84 age group. Trends in ASDR and ASMR showed an increase across most SDI regions, except Low SDI. Decomposition analysis and the APC model indicated poor control in high SDI regions due to aging populations over the past 5 years. By 2050, the global prevalence is projected to reach 1,003,018.047 (26124.40377, 12114480.49), with 345,342.5738 (1431.57781, 6022119.213) males and 657,675.4731 (24692.82596, 6092361.28) females. The Shiny platform predicts a yearly increase in ASDR and ASMR for HFPG-ADOD in China, which is consistent with GBD platform trends. The platform is accessible at http://116.196.73.86:3838/GBD/HFPG-ADOD/.ConclusionThe global burden of HFPG-related ADOD has been increasing, even in high SDI regions, over the past 5 years and is expected to continue rising until 2050. Implementing appropriate health policies to mitigate this trend could significantly reduce the substantial burden caused by HFPG-induced ADOD. Promoting the use of the Shiny prediction platform will contribute significantly to global healthy aging.

This statistic shows the percentage changes in selected causes of death due to diseases in the United States, between 2000 and 2022. The number of deaths caused by prostate cancer increased by 7.4 percent during this period. Changes in selected causes of deathThere has been a decrease in the rate of death caused by many diseases, including stroke and heart disease. However, the mortality rate due to Alzheimer’s disease increased by 142 percent from 2000 to 2022. Alzheimer’s disease caused 27.7 deaths per 100,000 population in 2023, making it the sixth leading cause of death in the United States. Mortality rates due to different diseases vary by different factors, including race and ethnicity. For example, cancer is the leading cause of death among Asians and Pacific Islanders in the United States, accounting for 22 percent of total deaths among this population, while heart disease is the leading cause of death among the white population. Ischemic heart disease is the leading cause of death worldwide, accounting for around nine million deaths in 2021. In the early 1900's, the mortality rate was primarily concentrated among people of younger ages, but increasingly, this has shifted to older population groups. In recent years, decreased mortality rates are often linked to improved medical care, such as new developments in medical technologies. Shifts in lifestyle habits such as decreased smoking rates and healthier diets may also attribute to lower mortality rates.

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

In 2023, there were around 17 deaths per 100,000 population among women in Canada due to Alzheimer's disease. This statistic displays the death rate for Alzheimer's disease in Canada from 2000 to 2023, by gender.

The Office for Health Improvement and Disparities (OHID) has updated the mortality profile.

The profile brings together a selection of mortality indicators, including from other OHID data tools such as the https://fingertips.phe.org.uk/profile/public-health-outcomes-framework/data" class="govuk-link">Public Health Outcomes Framework, making it easier to assess outcomes across a range of causes of death.

For the March 2023 update, 12 new indicators have been added to the profile:

• mortality rate for deaths due to COVID-19, all ages
• under 75 mortality rate for deaths due to COVID-19
• mortality rate from all cardiovascular diseases, all ages
• mortality rate from heart disease, all ages
• mortality rate from stroke, all ages
• mortality rate from cancer, all ages
• mortality rate from breast cancer, all ages
• mortality rate from colorectal cancer, all ages
• mortality rate from liver disease, all ages
• mortality rate from respiratory disease, all ages
• under 75 mortality rate from lung cancer
• mortality rate from dementia and Alzheimer’s disease, all ages

If you would like to send us feedback on the tool please contact pha-ohid@dhsc.gov.uk.

Examine predictors of clinical and resource utilization outcomes associated with Alzheimer’s disease and related dementias (ADRD), stratified by patient severity profiles. Cross-sectional study of adults (30+ year old) with ADRD discharged from US hospitals to home health care (HHC) and identified from the 2010–2015 Nationwide Readmissions Database (NRD) using ICD 9th-10th codes. Outcomes of interest included 30-day hospital readmissions, in-hospital mortality, and hospital length of stay (LOS). Covariates consisted of sociodemographic and clinical variables. Multiple logistic regressions (for readmissions and mortality) and generalized linear regressions (for LOS) were used to examine associations between outcomes and study covariates, stratified by patient severity profiles. Of 164,598 ADRD patients, 3,848 were mild, 68803 were moderate, 72428 were severe, and 19,519 were extreme. The 30-day readmission rate was 3.2%, death rate was 14.5%, and LOS was 3.0 days, (95%, CI: 15.0, 17.0) to 5.0 days, (95%, CI: 18.0, 19.0), all with a p-value

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the forecast period. This growth is largely driven by the increasing incidence of Alzheimer’s disease, an aging global population, innovations in drug discovery and development, and greater awareness and diagnosis of the condition. Additionally, the market’s expansion […]

FOR SINGLE DATA YEARS: Death rates are calculated based on the resident population of the data year involved. For census years, April 1 census counts are used (e.g. 2010). For postcensal years, July 1 estimates from the postcensal Vintage that matches the data year are used (e.g. July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011rates). For intercensal years, intercensal population estimates are used in rate calculations (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories.

Alzheimer’s disease (AD) is a progressive degenerating disease of complex etiology. A variety of risk factors contribute to the chance of developing AD. Lifestyle factors, such as physical, mental and social activity, education, and diet all affect the susceptibility to developing AD. These factors are in turn related to the level of personal income. Lower income usually coincides with lower level of education, lesser mental, leisure—social and physical activity, and poorer diet. In the present paper, we have analyzed the correlation of historical (1929–2011) per capita personal income (PCPI) for all states of the USA with corresponding age-adjusted AD death rates (AADR) for years 2000, 2005 and 2008. We found negative correlations in all cases, the highest one (R ≈ -0.65) for the PCPIs in the year 1970 correlated against the AADRs in 2005. From 1929 to 2005 the R value varies in an oscillatory manner, with the strongest correlations in 1929, 1970, 1990 and the weakest in 1950, 1980, 1998. Further analysis indicated that this oscillatory behavior of R is not artificially related to the economic factors but rather to delayed biological consequences associated with personal income. We conclude that the influence of the income level on the AD mortality in 2005 was the highest in the early years of life of the AD victims. Overall, the income had a significant, lifelong, albeit constantly decreasing, influence on the risk of developing AD. We postulate that the susceptibility of a population to late-onset AD (LOAD) is determined to a large extent by the history of income-related modifiable lifestyle risk factors. Among these risk factors, inappropriate diet has a significant contribution.

IRR* and IRR** denotes adjusted incidence rate ratio. IRR (95%CI) represents incident rate ratio and 95% confidence interval and were estimated using Poisson regression adjusted for country, sex, attained age, calendar period of observation and the interaction between country and calendar period of observation for adjusted model-1*. In adjusted model-2**, the model included additional adjustments for diabetes, stroke and myocardial infarction. Analyses were restricted to subjects with known blood group who were born in Sweden or Denmark. Blood group O is the reference category.Incidence rate ratio of Alzheimer's disease, vascular dementia, all dementia combined by ABO blood groups stratified according to attained age.

ABSTRACT Background : The Covid-19 pandemic associated with the SARS-CoV-2 has caused very high death tolls in many countries, while it has had less prevalence in other countries of Africa and Asia. Climate and geographic conditions, as well as other epidemiologic and demographic conditions, were a matter of debate on whether or not they could have an effect on the prevalence of Covid-19. Objective : In the present work, we sought a possible relevance of the geographic location of a given country on its Covid-19 prevalence. On the other hand, we sought a possible relation between the history of epidemiologic and demographic conditions of the populations and the prevalence of Covid-19 across four continents (America, Europe, Africa, and Asia). We also searched for a possible impact of pre-pandemic alcohol consumption in each country on the two year death tolls across the four continents. Methods : We have sought the death toll caused by Covid-19 in 39 countries and obtained the registered deaths from specialized web pages. For every country in the study, we have analysed the correlation of the Covid-19 death numbers with its geographic latitude, and its associated climate conditions, such as the mean annual temperature, the average annual sunshine hours, and the average annual UV index. We also analyzed the correlation of the Covid-19 death numbers with epidemiologic conditions such as cancer score and Alzheimer score, and with demographic parameters such as birth rate, mortality rate, fertility rate, and the percentage of people aged 65 and above. In regard to consumption habits, we searched for a possible relation between alcohol intake levels per capita and the Covid-19 death numbers in each country. Correlation factors and determination factors, as well as analyses by simple linear regression and polynomial regression, were calculated or obtained by Microsoft Exell software (2016). Results : In the present study, higher numbers of deaths related to Covid-19 pandemic were registered in many countries in Europe and America compared to other countries in Africa and Asia. The analysis by polynomial regression generated an inverted bell-shaped curve and a significant correlation between the Covid-19 death numbers and the geographic latitude of each country in our study. Higher death numbers were registered in the higher geographic latitudes of both hemispheres, while lower scores of deaths were registered in countries located around the equator line. In a bell shaped curve, the latitude levels were negatively correlated to the average annual levels (last 10 years) of temperatures, sunshine hours, and UV index of each country, with the highest scores of each climate parameter being registered around the equator line, while lower levels of temperature, sunshine hours, and UV index were registered in higher latitude countries. In addition, the linear regression analysis showed that the Covid-19 death numbers registered in the 39 countries of our study were negatively correlated with the three climate factors of our study, with the temperature as the main negatively correlated factor with Covid-19 deaths. On the other hand, cancer and Alzheimer's disease scores, as well as advanced age and alcohol intake, were positively correlated to Covid-19 deaths, and inverted bell-shaped curves were obtained when expressing the above parameters against a country’s latitude. Instead, the (birth rate/mortality rate) ratio and fertility rate were negatively correlated to Covid-19 deaths, and their values gave bell-shaped curves when expressed against a country’s latitude. Conclusion : The results of the present study prove that the climate parameters and history of epidemiologic and demographic conditions as well as nutrition habits are very correlated with Covid-19 prevalence. The results of the present study prove that low levels of temperature, sunshine hours, and UV index, as well as negative epidemiologic and demographic conditions and high scores of alcohol intake may worsen Covid-19 prevalence in many countries of the northern hemisphere, and this phenomenon could explain their high Covid-19 death tolls. Keywords : Covid-19, Coronavirus, SARS-CoV-2, climate, temperature, sunshine hours, UV index, cancer, Alzheimer disease, alcohol.